Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Statement on Nuplazid Drug

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis A broad medical term used to describe a loss of contact with reality that involves hallucinations and/or delusions. in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

The Parkinson’s Foundation is closely monitoring the recent reports on Nuplazid. At this time, we are recommending that patients on this drug consult with their neurologists about the risks and benefits of the treatment. The FDA will continue to monitor the drug’s use and safety, but they have not identified a specific safety issue that isn’t already described in the drug’s label. 

Parkinson’s disease psychosis is typically seen in advanced stages of Parkinson’s disease involving elderly patients. Treating Parkinson’s disease psychosis is a multi-step process that begins with talking to your health care team. They will follow a series of steps to figure out how best to address symptoms. For more information on this topic, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636). 

Please report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088. You can also call ACADIA Pharmaceuticals Inc. at 1‑844‑4ACADIA (1‑844‑422‑2342).

For more information about Psychosis and Parkinson’s Disease:

Listen to our podcast

Read our recent blog article

Read more in our free book, "Psychosis: A Mind Guide to Parkinson's Disease"

Watch our Expert Briefings: Parkinson's Disease Psychosis: Hallucinations, Delusions and Paranoia

Tuesday, April 10, 2018
Parkinson’s Disease Foundation Opens $500,000 in Grant Funding, Urges Scientists to Address Key Unmet Needs in Patient Community
Thursday, July 21, 2016

New Awards Fund Translational Patient-Driven Research Projects

Parkinson's Disease Foundation Invests in Next Generation of Patient Leaders
Friday, July 15, 2016

The Parkinson's Disease Foundation® (PDF®) is pleased to welcome 20 people with Parkinson's disease and care partners to its national research advocacy network. These individuals join more than 325 patient leaders who are helping PDF solve, treat and end Parkinson's disease.

The National Parkinson Foundation’s Moving Day® Walks Fund Parkinson’s Programs in Six Cities
Monday, June 27, 2016

MIAMI — The National Parkinson Foundation (NPF) is proud to announce that the 2015 fall walk season of Moving Day®, A Walk for Parkinson’s, has funded nearly $300,000 in mission services to make life better for people living with Parkinson’s and their caregivers in six communities.

NPF and Global Kinetics Corporation Announce the Commencement of a Clinical Trial to Study Impact of Personal KinetiGraph Use in Routine Clinical Care of Patients with Parkinson's Disease
Wednesday, June 22, 2016

A multi-center, randomized controlled trial to assess whether the use of continuous objective measurement of changes in mobility in patients with Parkinson’s disease can improve physician treatment decisions and patient outcomes.

The National Parkinson Foundation Partners with Honor to Help the Home Care Company Deliver Personalized Care in the Home
Tuesday, June 21, 2016

The National Parkinson Foundation (NPF) and Honor home care announced today a collaborative partnership to bring personalized care in the home to people diagnosed with Parkinson’s.  Honor will license the NPF’s proprietary care guidance.

The National Parkinson Foundation Announces New Findings from Largest-Ever Parkinson’s Study of 8,000 Patients Worldwide
Monday, June 20, 2016

Latest Data Point To Improve Patient Care Through Precision Treatment

PDF Research Advocates Guide $16 Million in Parkinson’s Research Funding
Wednesday, June 15, 2016

Recently, two Parkinson’s Disease Foundation (PDF) volunteers helped guide $16 million in government funding for Parkinson’s disease (PD) research.

This spring, Sam Erwin, M.S., M.A., of West Des Moines, IA, and Paul Zimmet, D.D.S., of Reston, VA – both PDF Research Advocates, people living with PD and US Army Veterans – served as consumer reviewers of research funded by the US Department of Defense (DoD).

Parkinson's Disease Foundation Announces $4 Million in Research Investments to Solve, Treat and End Parkinson's Disease
Thursday, June 9, 2016

Research Funding for Early-Career Scientists Reflects Urgent Need for Better Therapies

Adaptive Athlete Announces 300 Skydives in 24 Hours
Wednesday, June 8, 2016

“300 Imperfect Jumps” Raises Funds for Parkinson’s Disease Research

NPF Celebrates the Life and the Legend of Muhammad Ali
Saturday, June 4, 2016

MIAMI — Today we mourn the loss and celebrate the life of Muhammad Ali, a longtime friend of the National Parkinson Foundation (NPF). Mr. Ali passed away at age 74 after being hospitalized for respiratory problems, a common complication in advanced Parkinson’s disease.

Pages

mail icon

Subscribe here to get the latest news on treatments, research and other updates.